首页> 美国卫生研究院文献>Open Forum Infectious Diseases >A Review of the Global Burden New Diagnostics and Current Therapeutics for Amebiasis
【2h】

A Review of the Global Burden New Diagnostics and Current Therapeutics for Amebiasis

机译:阿米巴病的全球负担新诊断方法和当前疗法的综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Amebiasis, due to the pathogenic parasite is a leading cause of diarrhea globally. Largely an infection of impoverished communities in developing countries, amebiasis has emerged as an important infection among returning travelers, immigrants, and men who have sex with men residing in developed countries. Severe cases can be associated with high case fatality. Polymerase chain reaction–based diagnosis is increasingly available but remains underutilized. Nitroimidazoles are currently recommended for treatment, but new drug development to treat parasitic agents is a high priority. Amebiasis should be considered before corticosteroid therapy to decrease complications. There is no effective vaccine, so prevention focuses on sanitation and access to clean water. Further understanding of parasite biology and pathogenesis will advance future targeted therapeutic and preventative strategies.
机译:由于致病性寄生虫引起的阿米巴病是全球腹泻的主要原因。在发展中国家,贫困人口主要是感染,阿米巴病已成为返回的旅行者,移民和与发达国家男子有性关系的男子中的重要感染。严重的病例可能与较高的病例死亡率相关。基于聚合酶链反应的诊断越来越多,但仍未得到充分利用。目前推荐使用硝基咪唑类药物进行治疗,但是开发用于治疗寄生虫的新药物是当务之急。皮质类固醇激素治疗前应考虑阿米巴病,以减少并发症。没有有效的疫苗,因此预防重点在于卫生和获得清洁水。对寄生虫生物学和发病机制的进一步了解将促进未来的靶向治疗和预防策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号